A severe neurodevelopmental disorder mostly affecting girls. ...

• 1. Telethon Kids Institute
• Our research
• Research Topics

André Timo Anthony Kathryn Peter Sam Alex Bep Thomas Schultz Lassmann Kicic Ramsey Richmond Buckberry Brown Uink Iosifidis AS T A KR PC SB AB BU TI MBChB, PhD, FRACP BSc (Hons) MSc PhD BSc (Hons) PhD BSc (Hons), PhD MBBS MRCP(UK) FRACP BSc, BHlthSc ...

• 1. Telethon Kids Institute
• Projects

Genevieve Sarra Jenefer Syn Jamieson Blackwell GS SE JM BSc (Hons), PhD BSc (Hons) MSc PhD BSc with First Class Honours, PhD, DSc, FMedSci, FAA Research Officer Senior Research Fellow Head, Genetics & Health (08) 6319 1549 Genevieve.syn@ ...

• 1. Telethon Kids Institute
• Our research
• Past teams
• Genetics and Health

Rebecca Fiona Hannah Glauert Stanley Moore RA FJ HC BPsych (Hons) PhD FAA FASSA MSc MD FFPHM FAFPHM FRACP FRANZCOG HonDSc HonDUniv HonFRACGP HonMD HonFRCPCH HonLLB (honoris causa) OAM BSc (Hons) GradDipClinEpi PhD Honorary Research Associate Patron ...

• 1. Telethon Kids Institute
• Projects

Anthony Janessa Ruth Tim Kicic Pickering Thornton Barnett A Dr RT TB BSc (Hons) PhD BSc PhD PhD PhD Rothwell Family Fellow; Head, Airway Epithelial Research Senior Research Fellow (currently HOT NORTH Early Career Fellow) Co-head, Bacterial ...

• 1. Telethon Kids Institute
• Projects

Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• January 2023

Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• April 2021

Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• April 2021

Present a valuable resource for drug discovery and have identified ROM as a promising therapeutic for MLL-rearranged iALL ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2016
• January 2016

Australian Aboriginal and/or Torres Strait Islander children in rural/remote areas suffer high rates of persistent otitis media (OM) from early infancy. We aimed to determine the proportion of Aboriginal infants living in an urban area who have OM and investigate associated risk factors. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• February 2023

Yael Jacinta Penelope Keely Bep Amy Helen Claire Perry Freeman Strauss Bebbington Uink Finlay-Jones Milroy McIlroy YP JF PS KB BU AFJ HM CM BPsych (Hons) MPsych (Clin) PhD BScs, MPH BA, MPH, PhD MClinPsych/PhD BPsych(Hons.), MAppPsy(Clinical), PhD ...

• 1. Telethon Kids Institute
• Projects
• Past projects

Yael Bep Gail Francis Jenny Hayley Ben Penelope Samantha Perry Uink Alvares Mitrou Downs Passmore Jackson Strauss Speirs YP BU GA FG JA HP BJ PS SS BPsych (Hons) MPsych (Clin) PhD BPsych(Hons.), MAppPsy(Clinical), PhD PhD BEc BApplSci (physio) MSc ...

• 1. Telethon Kids Institute
• Projects